"10.1371_journal.pone.0067583","plos one","2013-07-03T00:00:00Z","Alastair J King; Marc R Arnone; Maureen R Bleam; Katherine G Moss; Jingsong Yang; Kelly E Fedorowicz; Kimberly N Smitheman; Joseph A Erhardt; Angela Hughes-Earle; Laurie S Kane-Carson; Robert H Sinnamon; Hongwei Qi; Tara R Rheault; David E Uehling; Sylvie G Laquerre","GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America; GlaxoSmithKline Department of Enzymology & Mechanistic Pharmacology, Collegeville, Pennsylvania, United States of America; GlaxoSmithKline Portfolio Management, Collegeville, Pennsylvania, United States of America; GlaxoSmithKline Department of Safety Assessment, King of Prussia, Pennsylvania, United States of America; GlaxoSmithKline Department of Screening & Compound Profiling, GlaxoSmithKline, Durham, North Carolina, United States of America; GlaxoSmithKline Department of Biological Reagents & Assay Development, King of Prussia, Pennsylvania, United States of America; GlaxoSmithKline Department of Medicinal Chemistry, GlaxoSmithKline, Durham, North Carolina, United States of America","Conceived and designed the experiments: AJK MRA MRB JY JAE SGL TRR DEU. Performed the experiments: MRA MRB KGM JY KEF KNS AHE LSKC RHS HQ. Analyzed the data: AJK AHE SGL. Contributed reagents/materials/analysis tools: TRR DEU. Wrote the paper: AJK SGL.","The authors are specifying that at the time the research was performed, all authors were GlaxoSmithKline (GSK) employees and received compensation from GSK. GSK also funded the research and financed patent applications linked to the discoveries described in the manuscript. GSK intends to commercialize dabrafenib, pending approval. GSK will adhere to all the PLOS ONE policies on sharing data and materials for non-human research purposes.","2013","07","Alastair J King","AJK",15,TRUE,8,10,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
